Literature DB >> 18226731

Hyperprolactinemia and prolactinomas.

Tatiana Mancini1, Felipe F Casanueva, Andrea Giustina.   

Abstract

Any process interfering with dopamine synthesis, its transport to the pituitary gland, or its action at the level of lactotroph dopamine receptors can cause hyperprolactinemia. As described in this article, considering the complexity of prolactin regulation, many factors could cause hyperprolactinemia, and hyperprolactinemia can have clinical effects not only on the reproductive axis. Once any drug effects are excluded, prolactinomas are the most common cause of hyperprolactinemia. The most frequent symptom is hypogonadism in both genders. Medical and surgical therapies generally have excellent results, and most prolactinomas are well controlled or even cured in some cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226731     DOI: 10.1016/j.ecl.2007.10.013

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  65 in total

1.  Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database.

Authors:  Thierry Trenque; Emmanuelle Herlem; Pascal Auriche; Moustapha Dramé
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

2.  Ectopic posterior pituitary causing hyperprolactinemia.

Authors:  D Iacovazzo; F Lugli; A Giampietro
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

3.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

Review 4.  The management of the patient with acromegaly and headache: a still open clinical challenge.

Authors:  A Giustina; M Gola; A Colao; L De Marinis; M Losa; N Sicolo; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

5.  Pituitary testing: a reappraisal.

Authors:  Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 6.  Diagnosis and Management of pituitary disease with focus on the role of Magnetic Resonance Imaging.

Authors:  Amit Mahajan; Richard A Bronen; Ali Y Mian; Sacit Bulent Omay; Dennis D Spencer; Silvio E Inzucchi
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

Review 7.  Primary empty sella: Why and when to investigate hypothalamic-pituitary function.

Authors:  A Giustina; G Aimaretti; M Bondanelli; F Buzi; S Cannavò; S Cirillo; A Colao; L De Marinis; D Ferone; M Gasperi; S Grottoli; T Porcelli; E Ghigo; E degli Uberti
Journal:  J Endocrinol Invest       Date:  2010-03-05       Impact factor: 4.256

8.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 9.  Double pituitary adenomas.

Authors:  D Iacovazzo; A Bianchi; F Lugli; D Milardi; A Giampietro; E Lucci-Cordisco; F Doglietto; L Lauriola; L De Marinis
Journal:  Endocrine       Date:  2013-01-17       Impact factor: 3.633

10.  Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.

Authors:  Aysegul Atmaca; Birsen Bilgici; Gulcin Cengiz Ecemis; Ozgur Korhan Tuncel
Journal:  Endocrine       Date:  2013-03-26       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.